Financial Data and Key Metrics Changes - As of June 30, 2025, the company's cash position was $42.3 million, expected to support operations into 2027 [20] - Total revenues for Q2 2025 were $2.8 million, a net increase of $1.4 million compared to $1.4 million for the same period in 2024, primarily driven by collaboration revenue from the Roche agreement [22] - Operating expenses were $22.5 million, an increase of $5.2 million compared to $7.3 million for the same period in 2024, largely due to a non-cash impairment expense of $14.8 million related to the VAC platform [22][24] - The net loss was $30.5 million or $0.13 per share, compared to a net loss of $5.8 million or $0.03 per share for the same period in 2024 [24] Business Line Data and Key Metrics Changes - The OpRegen program showed a mean gain of vision of nine letters in treated patients over three years, contrasting with an 11-letter loss in untreated eyes, indicating a significant treatment effect [6][7] - The OPC1 program has been administered to 31 individuals with acute severe spinal cord injuries, with promising long-term safety and efficacy data [15] Market Data and Key Metrics Changes - The company noted that there are now four independent groups reporting vision gains from RPE cell transplants, validating the potential of the OpRegen program [8] - The ongoing phase 2a clinical trial run by Genentech is expected to provide insights into surgical procedures and delivery methods, enhancing the company's competitive position [9] Company Strategy and Development Direction - The company is exploring new therapeutic areas to leverage its directed differentiation expertise and recent manufacturing accomplishments, aiming to diversify its pipeline beyond OpRegen [10][11] - The strategy includes entering into deals that fund existing product candidates, creating new assets, and obtaining grants to reduce dependency on equity capital markets [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of OpRegen to drive positive clinical outcomes and highlighted the importance of independent evidence from other RPE cell transplant trials [26] - The company is focused on ensuring that OPC1 has the necessary attributes for later-stage clinical testing and is optimistic about the ongoing developments [26] Other Important Information - The company has a GMP banking and production platform capable of generating millions of doses of product candidates, which is a significant competitive advantage [8] - The company is actively pursuing non-dilutive funding sources, including milestone payments and program grants [21] Q&A Session Summary Question: Context on the dose study and patient enrollment - Management indicated that predicting enrollment is challenging due to limited experience with chronic patients, but they are optimistic about patient interest in the trial [31][32] Question: Enrollment in the Phase 2a study - Management refrained from commenting on enrollment specifics but emphasized ongoing efforts to ensure effective patient recruitment [38] Question: Manufacturing progress and potential partnerships - Management noted that manufacturing is a core focus for 2025 and they expect to see valuable outcomes from their strategies by year-end [38] Question: Preclinical data from the hearing loss program - Management confirmed that preclinical work is ongoing, but no specific timeline for reportable data was provided [51] Question: Expansion of sites for the dose study - Management stated that they are focusing on experienced sites and have already initiated the process for a second site [68] Question: Follow-up duration for patients - Management confirmed that they plan to follow patients for at least ten years, emphasizing the importance of long-term data collection [71] Question: Differences in benefit thresholds for chronic vs. subacute patients - Management acknowledged that chronic patients may have different clinical meaningfulness thresholds compared to subacute patients, which will be considered in data analysis [75]

Financial Data and Key Metrics Changes - As of March 31, 2025, the company's cash position was $47.9 million, expected to support operations into Q1 2027 [24] - Total revenues for Q1 2025 were $1.5 million, a net increase of $0.1 million compared to $1.4 million for the same period in 2024, primarily driven by collaboration revenue from Roche [25] - Operating expenses for Q1 2025 were $8 million, a decrease of $0.1 million compared to $8.1 million in Q1 2024 [26] - The net loss for Q1 2025 was $4.1 million or $0.02 per share, compared to a net loss of $6.5 million or $0.04 per share for the same period in 2024 [26] Business Line Data and Key Metrics Changes - OpRegen is currently in a Phase 2a study called the GALET study, which is exploring surgical delivery parameters to optimize the risk-benefit profile [8] - The OPC1 program has been tested in 30 individuals with severe spinal cord injuries, with promising long-term safety and efficacy data [18] Market Data and Key Metrics Changes - The company is encouraged by recent independent validation from competing RPE companies, indicating that RPE transplants can drive clinical outcomes beyond currently approved therapies [13] - Genentech plans to report three-year data from the Phase 1/2a trial of OpRegen, which is expected to provide additional support for the treatment's efficacy [10] Company Strategy and Development Direction - The company aims to capitalize on its investments in cell manufacturing and expand its capabilities through partnerships beyond OpRegen and OPC1 [29] - The manufacturing platform is seen as a competitive advantage, allowing for low-cost production of allogeneic therapies [15] Management's Comments on Operating Environment and Future Outlook - Management remains confident in OpRegen's potential to drive positive clinical outcomes in dry AMD and is encouraged by partners' commitment to the program [28] - The company is optimistic about the future of cell and gene therapies, especially in light of supportive regulatory comments from the new CBER director [84] Other Important Information - The company has completed GMP production runs of a product candidate from a single pluripotent cell line, marking a significant achievement in manufacturing capabilities [16] - The company is collaborating with the Christopher and Dana Reeve Foundation for the third annual SCI Investor Symposium, which will be held virtually [22] Q&A Session Summary Question: Can you compare your manufacturing capabilities to peers? - The CEO noted that direct comparisons are challenging as many peers do not disclose sufficient details about their capabilities, but emphasized that the company's manufacturing system is highly differentiated [33][36] Question: What potential tariff impacts might you expect with your manufacturing site in Israel? - The CFO indicated that they do not expect tariff impacts and have measures in place to mitigate production issues by purchasing materials in advance [38] Question: Can you elaborate on potential partnership opportunities related to your new manufacturing capabilities? - The CEO mentioned that each opportunity will be specific, and the company is not aiming to become a contract manufacturer but is open to collaborations that could involve success payments and ownership in assets [45][46] Question: When might we expect data from the OPC1 program? - The CEO stated that initial safety data from the dose study would be available within 30 days, while functional assessments would take longer, typically 6 to 12 months [54][55] Question: What does a successful delivery outcome look like for the OPC1 dose study? - The CEO explained that success will largely depend on the usability of the new delivery device and the absence of unexpected complications, with a focus on enabling a better surgical delivery method [62] Question: Can you comment on the design of the spinal cord injury trial? - The CEO provided details on the staggered enrollment process, indicating that the first three patients will be thoracic injury patients, followed by cervical patients, before moving to open enrollment [86]

Financial Data and Key Metrics Changes - As of March 31, 2025, the company's cash position was $47.9 million, expected to support operations into Q1 2027 [23] - Total revenues for Q1 2025 were $1.5 million, a net increase of $0.1 million compared to $1.4 million for the same period in 2024, primarily driven by collaboration revenue from Roche [24] - Operating expenses for Q1 2025 were $8 million, a decrease of $0.1 million compared to $8.1 million in Q1 2024 [24] - The net loss for Q1 2025 was $4.1 million or $0.02 per share, compared to a net loss of $6.5 million or $0.04 per share for the same period in 2024 [25] Business Line Data and Key Metrics Changes - OpRegen is currently in a Phase 2a study called the GALET study, which is exploring various parameters of surgical delivery [7] - The OPC1 program has been tested in 30 individuals with severe spinal cord injuries, with promising long-term safety and efficacy data [18] Market Data and Key Metrics Changes - The company is encouraged by recent positive data from competing RPE companies, which supports the potential of RPE transplants to drive clinical outcomes beyond currently approved therapies [13] Company Strategy and Development Direction - The company aims to capitalize on investments in cell manufacturing and expand capabilities through partnerships beyond OpRegen and OPC1 [27] - The manufacturing platform is seen as a competitive advantage, allowing for low-cost production of allogeneic therapies [15] Management's Comments on Operating Environment and Future Outlook - Management remains confident in OpRegen's potential to drive positive clinical outcomes in dry AMD and is encouraged by partners' commitment to the program [27] - The company is preparing for success by seeking additional partnerships and funding opportunities [27] Other Important Information - The company has completed GMP production runs capable of producing millions of doses from a single cell line, marking a significant achievement in manufacturing capabilities [16] Q&A Session Summary Question: Comparison of manufacturing capabilities with peers - Management expressed frustration over the lack of detailed comparisons from peers but emphasized their differentiated capabilities in manufacturing [31][33] Question: Potential tariff impacts due to manufacturing site in Israel - Management does not expect tariff impacts and has measures in place to mitigate production issues [36][37] Question: Thoughts on potential partnerships around new manufacturing capabilities - Management indicated that partnerships would vary by opportunity, focusing on success payments and ownership in assets rather than becoming a contract manufacturer [44] Question: Expected data from the OPC1 program - Initial data from the dose study is expected to be available within 30 days, with functional assessments potentially lagging by several months [54] Question: Design of the spinal cord injury trial - The trial will enroll between six and ten patients, with a staggered approach for thoracic and cervical patients [90]

Financial Data and Key Metrics Changes - As of December 31, 2024, the company reported year-end cash, cash equivalents, and marketable securities of $47.8 million, along with approximately $5.5 million in net proceeds from a financing event [40] - Total revenues for Q4 2024 were approximately $2.9 million, a net increase of $0.8 million compared to $2.1 million for the same period in 2023 [43] - The net loss attributable to the company for Q4 was $3.3 million or $0.02 per share, compared to a net loss of $4.8 million or $0.03 per share for the same period in 2023 [46] Business Line Data and Key Metrics Changes - R&D expenses for Q4 2024 were $3.4 million, a decrease of $0.5 million compared to $3.9 million for the same period in 2023, primarily driven by a decrease in OPC1 program expenses [44] - Total operating expenses for Q4 were $7.8 million, a decrease of $0.4 million compared to $8.2 million for the same period in 2023 [44] Market Data and Key Metrics Changes - The company noted an increase in OpRegen activity, with Roche and Genentech entering into an additional agreement to provide services for manufacturing and long-term follow-up of Phase 1/2a patients [11][12] - The ongoing GAlette Study has been enrolling for nearly two years, indicating a significant amount of data should be available for decision-making [10] Company Strategy and Development Direction - The company is focused on scalable GMP manufacturing, which is crucial for the success of allogeneic cell therapy products [22][30] - The company aims to establish a leading position in allogeneic process development and production, emphasizing the need for large-scale production capabilities [29][30] - The company is advancing its second clinical stage allogeneic program, OPC1, with plans for a larger clinical trial in spinal cord injury [31][37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for OpRegen to drive positive clinical outcomes in dry AMD, supported by independent evidence from other RPE transplant trials [52] - The company is strategically balancing cost and investment while exploring other potential funding sources, including milestone payments and program grants [42][90] Other Important Information - The company has continued to add value to its patent portfolio, with two additional OpRegen patents issued earlier this year [38] - The company is preparing for a clinical study called the DOSED Study to test a novel delivery device for OPC1, which is expected to enhance the administration process [34][37] Q&A Session Summary Question: What is the company doing to protect its market leadership in RPE cell placements? - Management emphasized the importance of having the right attributes for success, highlighting the combination of Lineage's manufacturing, Genentech's product development, and Roche's commercialization capabilities as a competitive advantage [59][61] Question: When will the updated three-year data for OpRegen be available? - Management indicated that inquiries regarding the timeline for the three-year data should be directed to Genentech, as they control the announcement schedule [64] Question: Can you describe any changes in logistics for getting patients to the surgical suite faster? - Management noted improvements in training and the development of an immediate use formulation to streamline the process, reducing preparation time for cell administration [77][78] Question: Will the FDA require proof of device safety before fully enrolling across all planned sites for the DOSED study? - Management confirmed that there is a staging process, starting with a few patients before moving to broader enrollment [83] Question: What are the plans for the resonance program given market uncertainty? - Management stated that while the resonance program remains important, they are being prudent with investment decisions in the current market environment [88][90]